It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Fucoidans (FUCs) are highly sulfated polysaccharides demonstrating multiple actions in different systems. Oxaliplatin (OXA) is a platinum-containing chemotherapeutic agent with several side effects that restrict its usage. The current study aimed to determine the potential effect of FUC in male rats with splenic dysfunction induced by OXA. Eighty adult male rats aged (8–9 weeks) weighing (190–230 g) were divided into four groups: (Group I: the control group): Rats were administrated normal saline; (Group II: controls treated by FUC): Rats were treated with FUC; (Group III: Splenic dysfunction group): Rats were treated with 8 mg/kg OXA. (IV: Splenic dysfunction treated by FUC): Rats were treated by OXA as Group III, then fucoidan was given. At the end of the experiment, blood was collected to determine red blood cells and white blood cells. Splenic tissues were divided into one part for biochemical assays, oxidative stress markers as MDA and catalase, inflammatory markers (TNF-alpha, IL6), and apoptotic markers (caspase 3) and gene expression of Nrf2, Mapk1 gene expression, and endoplasmic stress parameters and the other part was used for immunohistochemical and histopathological analysis. Compared to the OXA-induced splenic dysfunction group, FUC significantly decreased high levels of MDA, TNF- alpha, IL6, caspase-3, Mapk1, endoplasmic stress induced by OXA, and increased the level of catalase and Nrf2. Fucoidan has corrected the histopathological and immunohistochemical changes compared to the OXA-induced splenic dysfunction group. In conclusion, our findings suggest that fucoidan has a significant role in the treatment of splenic dysfunction induced by OXA.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Tanta University, Department of Medical Physiology, Faculty of Medicine, Tanta, Egypt (GRID:grid.412258.8) (ISNI:0000 0000 9477 7793)
2 Tanta University, Department of Medical Biochemistry, Faculty of Medicine, Tanta, Egypt (GRID:grid.412258.8) (ISNI:0000 0000 9477 7793)
3 Tanta University, Department of Internal Medicine, Faculty of Medicine, Tanta, Egypt (GRID:grid.412258.8) (ISNI:0000 0000 9477 7793)
4 Tanta University, Department of Pathology, Faculty of Medicine, Tanta, Egypt (GRID:grid.412258.8) (ISNI:0000 0000 9477 7793)
5 Tanta University, Department of Clinical Oncology, Faculty of Medicine, Tanta, Egypt (GRID:grid.412258.8) (ISNI:0000 0000 9477 7793)
6 Tanta University, Department of Anatomy, Faculty of Medicine, Tanta, Egypt (GRID:grid.412258.8) (ISNI:0000 0000 9477 7793)
7 Tanta University, Department of Medical Pharmacology, Faculty of Medicine, Tanta, Egypt (GRID:grid.412258.8) (ISNI:0000 0000 9477 7793)